RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Radiation and immunotherapy team up against hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments wil…
Matched conditions: RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC